<p><strong>Pediatric use</strong>: The safety and efficacy of Atezolizumab in children and adolescents below 18 years of age have not been established.<br />
<br />
<strong>Geriatric use</strong>: Based on a population pharmacokinetic analysis, no dose adjustment of Atezolizumab is required in patients &ge; 65 years of age<br />
<br />
<strong>Renal impairment</strong>: Based on a population pharmacokinetic analysis, no dose adjustment is required in patients with renal impairment<br />
<br />
<strong>Hepatic impairment</strong>: Based on a population pharmacokinetic analysis, no dose adjustment is required for patients with mild hepatic impairment. There are no data in patients with moderate or severe hepatic impairment</p>